19579-83-0

Basic information

• Product Name: 5H-Dibenz[b,f]azepine-10,11-dione
• Synonyms: 5H-Dibenz[b,f]azepine-10,11-dione;Dibenzazepine-10,11-dione;Dibenzazepinodione;Oxcarbazepine IMpurity (5H-Dibenz[b,f]azepine-10,11-dione);Oxcarbazepine Impurity 7;Oxcarbazepine EP Impurity D
• CAS NO: 19579-83-0
• Molecular Formula: C₁₄H₉NO₂
• Molecular Weight: 223.23
• Mol File: 19579-83-0.mol
• Article Data: 6

Chemical Properties

• Appearance: /
• Storage Temp.: Refrigerator
• Solubility: DMSO (Slightly)
• CAS DataBase Reference: 5H-Dibenz[b,f]azepine-10,11-dione(CAS DataBase Reference)
• NIST Chemistry Reference: 5H-Dibenz[b,f]azepine-10,11-dione(19579-83-0)
• EPA Substance Registry System: 5H-Dibenz[b,f]azepine-10,11-dione(19579-83-0)

Safety Data

• Hazardous Substances Data: 19579-83-0(Hazardous Substances Data)

Usage

Description

5H-Dibenz[b,f]azepine-10,11-dione is an organic compound with the chemical formula C14H11NO2. It is a dark yellow solid and is known for its use in various applications, particularly in the field of optoelectronics.

Uses

Used in Optoelectronic Applications:
5H-Dibenz[b,f]azepine-10,11-dione is used as a reagent in the preparation of bifunctional dipolar electroluminescent templates. These templates are crucial for the development of advanced optoelectronic devices, which are essential in various industries, including telecommunications, display technology, and lighting.
Used in Pharmaceutical Industry:
As an impurity of Oxcarbazepine (O869250), 5H-Dibenz[b,f]azepine-10,11-dione plays a role in the pharmaceutical industry. Oxcarbazepine is a medication used to treat certain types of epilepsy, and the presence of this compound may affect the drug's efficacy and safety. Therefore, its control and management are essential in the manufacturing process of Oxcarbazepine.

Upstream product

• 118-92-3 anthranilic acid 
• 88-65-3 2-bromobenzoic-acid 
• 579-92-0 Vanadox 
• 49579-63-7 diphenylamine-2,2′-dicarboxaldehyde 
• 89023-35-8 2,2'-iminobis(hydroxymethylbenzene) 
• 34069-89-1 methyl 2‐[2‐(methoxycarbonyl)phenylamino]benzoate 
• 298-46-4 carbamazepin 
• 494-19-9 9,10-dihydrodibenzazepine 
• 13080-75-6 5-acetyliminodibenzyl 
• 28721-07-5 oxcarbazepine 
• 256-96-2 dibenzoazepine 
• 56211-73-5 10,11-dihydro-5H-dibenzo[b,f]azepine-10,11-diol 
• 866181-35-3 11-hydroxy-5,11-dihydro-dibenzo[b,f]azepin-10-one 
• 127-08-2 potassium acetate 

Relevant articles and documents

Oxidation of carbamazepine by lipopathic Mn(VII), cetyltrimethylammonium permanganate: A mechanistic study

In this contribution, we report the oxidation of an established anticonvulsant and antiepileptic drug, carbamazepine, by a lipopathic oxidant, cetyltrimethylammonium permanganate (CTAP), in a nonpolar medium. 1H-Dibenzo[b,f]azepine-4,5-dione is found to be the major product of the oxidation reaction. The kinetics of the reaction is studied in organic media spectrophotometrically by monitoring the disappearance of Mn(VII) at 530 nm. The reaction is found to be fractional order with respect to carbamazepine and first order with respect to CTAP. Based on the experimental findings, a suitable ionic mechanism is proposed where carbamazepine reacts with CTAP in a slow rate-determining step to form a hypomanganate ester intermediate through a nonpolar cyclic transition state. Subsequently, the intermediate decomposes and hydrolyzes in fast steps to the dicarbonyl product. The proposed reaction mechanism is also supported by the effect of solvent and temperature on the rate of the reaction. The addition of ionic surfactants increases the rate of reaction, and the catalyzing effect is explained through the possible formation of mixed reverse micellar aggregates where carbamazepine is partitioned more to the interfacial region in the vicinity of the permanganate anion.

Complementation of biotransformations with chemical C-H oxidation: Copper-catalyzed oxidation of tertiary amines in complex pharmaceuticals

The isolation, quantitation, and characterization of drug metabolites in biological fluids remain challenging. Rapid access to oxidized drugs could facilitate metabolite identification and enable early pharmacology and toxicity studies. Herein, we compared biotransformations to classical and new chemical C-H oxidation methods using oxcarbazepine, naproxen, and an early compound hit (phthalazine 1). These studies illustrated the low preparative efficacy of biotransformations and the inability of chemical methods to oxidize complex pharmaceuticals. We also disclose an aerobic catalytic protocole (CuI/air) to oxidize tertiary amines and benzylic CH's in drugs. The reaction tolerates a broad range of functionalities and displays a high level of chemoselectivity, which is not generally explained by the strength of the C-H bonds but by the individual structural chemotype. This study represents a first step toward establishing a chemical toolkit (chemotransformations) that can selectively oxidize C-H bonds in complex pharmaceuticals and rapidly deliver drug metabolites.